Clinical use of cisapride and its risk-benefit in paediatric patients.
This paper provides a comprehensive review of the current knowledge on cisapride in different clinical conditions in children: different manifestations of gastro-oesophageal reflux, such as (excessive) regurgitation, oesophagitis, chronic respiratory disease or uncontrolled asthma, cystic fibrosis, chronic dyspepsia, constipation and pseudo-obstruction, and as an aid to small bowel capsule-biopsy. It discusses, in depth, the safety profile of cisapride in paediatric patients.
Vandenplas
Y
Y
Academic Children's Hospital, Free University of Brussels, Belgium.
D002648:Child; D002675:Child, Preschool; D020117:Cisapride / Q000009:adverse effects / Q000627:therapeutic use*; D003248:Constipation / Q000188:drug therapy; D003550:Cystic Fibrosis / Q000188:drug therapy; D004347:Drug Interactions; D004415:Dyspepsia / Q000188:drug therapy; D005242:Fecal Incontinence / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005772:Gastrointestinal Transit / Q000187:drug effects; D006801:Humans; D007223:Infant; D007415:Intestinal Obstruction / Q000188:drug therapy; D007418:Intestinal Pseudo-Obstruction / Q000188:drug therapy; D018570:Risk Assessment
D020117:Cisapride